Rion Co., Ltd. (RIOXF)
OTCMKTS
· Delayed Price · Currency is USD
14.60
0.00 (0.00%)
At close: May 27, 2025
Rion Co., Ltd. Revenue
In the fiscal year ending March 31, 2025, Rion Co., Ltd. had annual revenue of 27.88B JPY with 8.36% growth. Rion Co., Ltd. had revenue of 7.39B in the quarter ending March 31, 2025, with 2.34% growth.
Revenue
27.88B JPY
Revenue Growth
+8.36%
P/S Ratio
1.07
Revenue / Employee
27.17M JPY
Employees
1,026
Market Cap
199.02M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.88B | 2.15B | 8.36% |
| Mar 31, 2024 | 25.73B | 1.86B | 7.78% |
| Mar 31, 2023 | 23.87B | 1.23B | 5.45% |
| Mar 31, 2022 | 22.64B | 2.17B | 10.60% |
| Mar 31, 2021 | 20.47B | -999.00M | -4.65% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |